AiM Medical Robotics Secures $8.1 Million in Series A Funding to Revolutionize Neurosurgery with MRI-Compatible Robotics
AiM Medical Robotics Secures $8.1 Million Series A Financing Round
In a significant advancement for neurosurgery technology, AiM Medical Robotics Inc. has successfully closed an $8.1 million Series A financing round. The round, which attracted both new and returning investors, was led by IQ Capital from London, UK, and 1540 Ventures from New York, USA. This achievement signals a promising future for the company and for advancements in MRI-compatible surgical robotic systems.
Advancing Neurosurgery with Innovative Technology
Alex Wilson, Partner at IQ Capital, expressed confidence in AiM’s revolutionary approach, stating, “AiM is advancing neurosurgery with a novel robotic platform that integrates seamlessly into existing workflows and provides surgeons with real-time imaging to achieve safer, more precise, and more consistent outcomes for patients.” This technology is poised to transform surgical practices by enabling procedures directly within an MRI, which addresses intraoperative shifts and eliminates the risks associated with moving patients between operating rooms and imaging suites.
The Breakthrough System
AiM’s innovative robotic platform leverages real-time intraoperative MRI coupled with robotic guidance. This allows for precision in placement of neurostimulation leads, offering potential relief for Parkinson’s disease patients. Beyond neurostimulator lead placement, the system extends its utility to a variety of cranial procedures, including tumor ablation, biopsy, and the targeted intracranial delivery of novel therapeutics. This multifaceted approach promises not only to improve surgical speed and accuracy but also to reduce patient risks and healthcare costs.
A Robust Investment Landscape
The Series A funding, which closed initially in June 2025, included $3.75 million in notes converted to equity. A diverse group of world-class investors participated, including institutions like Worcester Polytechnic Institute and brain cancer impact investors such as the Sontag Innovation Fund and Cancer Research Horizons. Prominent angel groups like New York Angels and Harvard Business School Alumni Angels also contributed, demonstrating widespread confidence in AiM’s vision. With this financing, AiM has raised over $11.3 million in total investments so far, further supported by significant federal grants.
Looking Ahead
“This investment marks the beginning of the next chapter for AiM as we prepare to bring our transformative technology to patients,” said Dr. Gregory Fischer, co-founder and CEO of AiM Medical Robotics, Inc. As the company gears up for first-in-human trials, the emphasis will be on demonstrating the platform’s clinical and commercial potential across a range of cranial procedures, not only for Parkinson’s disease but also for conditions like epilepsy and cancer.
The proceeds from the Series A financing will support AiM’s first-in-human clinical study, bolster strategic partnerships, and accelerate product development and regulatory processes.
About AiM Medical Robotics
Based in Worcester, MA, AiM Medical Robotics is pioneering the development of next-generation MRI-compatible robotics for neurosurgery. The company’s compact, portable robotic platform is designed to integrate seamlessly into existing clinical workflows while enabling continuous, real-time visualization during surgery. The vision for the future includes harnessing artificial intelligence to create an intelligent surgical ecosystem that optimizes workflows and provides surgeons with predictive insights, ultimately revolutionizing brain surgery.
As AiM Medical Robotics continues to make strides, their initial target market—DBS neurostimulator lead placement—opens doors to an estimated $7.9 billion opportunity, unlocking the potential for more accessible and advanced surgical options for patients.
For more information on AiM Medical Robotics and their groundbreaking neurosurgical robotics platform, visit aimmedicalrobotics.com and follow them on LinkedIn.
This milestone marks a pivotal moment in the fusion of technology and healthcare, illustrating the potential for robotics to redefine surgical practices and improve patient outcomes.